A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC

NCT04514835 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Cisplatin+Capecitabine+Sintilimab

Sponsor

The First Affiliated Hospital of Zhengzhou University